Divamics Secures Tens of Millions in Series A Funding to Accelerate AI-Driven Innovative Drug Discovery

Recently, Divamics Inc. (hereinafter referred to as "Divamics") has completed a multi-million yuan A round of financing. The funds raised will be used to accelerate the iteration and upgrading of the technology platform and expand the global drug cooperation pipeline.

Divamics Inc., established in 2021, has developed a next-generation drug discovery and development platform based on multi-scale molecular dynamics combined with innovative algorithms. It provides a variety of computational and simulation services, including but not limited to highly flexible target modeling, target druggability analysis, large and small molecule drug structure screening, design, optimization, and particularly molecular mechanism interpretation. It offers novel drug molecular structure design and optimization solutions targeting so-called "undruggable" targets.

As a "technical dark horse" in the AIDD (AI-driven Drug Discovery and Design) field, Divamics has built differentiated competitiveness in frontier areas such as protein degraders, GPCR targets, and nucleic acid drugs through the deep integration of "multi-scale molecular dynamics + AI algorithms." Its core technology system overcomes the limitations of traditional static structure prediction by simulating the dynamic conformational changes of biomolecules (such as protein flexibility, induced fit upon ligand binding), providing atomic-level mechanistic insights for drug design.

Technically, Divamics' self-developed first-generation AI drug design algorithm has officially been granted a U.S. patent. The algorithm uses deep learning to create fingerprint models for each atom type in drugs and target molecules, offering strong interpretability. It is adept at uncovering unknown mechanisms at the molecular level, easily discovering new conformations and binding pockets for allosteric drugs, and can rationally design based on macromolecular flexibility, making it suitable for drug development across different modalities.

Building on this breakthrough, Divamics has further completed the framework construction of the world’s first kinetic trajectory database. By integrating big data related to drug development, it uncovers the underlying molecular mechanisms behind the pharmacodynamics and pharmacology of different pipelines, efficiently analyzes clinical and patent information, and precisely guides the logic chain of new drug development. It reshapes the innovative chain from molecular discovery to clinical validation, ensuring that drug molecules possess inherent clinical efficacy potential.

Regarding the acquisition of this round of financing, Zheng Zhen, founder of Divamics, stated: Divamics is committed to improving the R&D efficiency of innovative drugs. Our unique technical approach deeply integrates AI with physical simulations, aiming for a more precise understanding of the dynamic interactions and mechanisms between drug molecules and their targets, enabling rational drug design, efficacy prediction, and drug-likeness evaluation, thereby breaking through traditional bottlenecks in drug discovery. Over the past three years, we have continuously iterated and upgraded our core platform, achieving positive results through collaboration with dozens of global enterprises, validating the technical feasibility and potential, and demonstrating a clear value proposition and growth prospects. This round of financing marks further market recognition of the company’s technical strength, business model, and team execution capabilities, indicating that the company has entered a more mature stage of value creation. Leveraging this round of financing, we will further expand the types of targets and drug modalities our platform can handle and establish an operational management system to support global strategic partnerships. All members of Divamics will continue to spare no effort, driving profound transformation in the pharmaceutical industry through continuous innovation and open collaboration, ultimately benefiting patients worldwide.